Martin Beaulieu's Biography

Martin Beaulieu, Director, Regulus Therapeutics Inc

Dr. Martin Beaulieu is a biochemist with expertise in the development of molecular applications and diagnostic assay development. In the past 16 years, Dr. Beaulieu has led research & development activities in academic and bio-pharmaceutical organizations. He holds a Bachelor of Science degree in Biochemistry (1993) from Laval University and a Ph.D. in Physiology-Endocrinology from the Faculty of Medicine (1998) at Laval University.
Dr. Beaulieu’s Ph.D. thesis focused on steroid hormones and drug metabolizing enzymes, called UGTs. His work contributed to the demonstration of the role of the UGT enzymes in controlling steroid hormones homeostasis and cellular hormonal response in cancer cells. He authored 20 peer-reviewed scientific publications. During a post-doctoral fellowship, Dr. Beaulieu developed a novel mutation detection assay at the Beckman Research Institute at the City of Hope National Medical Center in Duarte, CA. At Sequenom Inc., a genetic systems company in San Diego, he led the development and optimization of molecular applications based on MALDI-TOF Mass Spectrometry including the iPLEXTM genotyping product. At DiagnoCure Inc. Dr. Beaulieu led cancer biomarker discovery studies and the development of a high-value molecular diagnostic test for staging colorectal cancer (Previstage™). Recently, Dr. Beaulieu supported the management of diagnostic assay development at Abbott Point of Care and is currently leading the Regulus microMarkers™ R&D division at Regulus Therapeutics Inc.